Literature DB >> 17950927

The ubiquitin-proteasome pathway in health and disease of the nervous system.

Ashok N Hegde1, Sudarshan C Upadhya.   

Abstract

In recent years, proteolysis by the ubiquitin-proteasome pathway has attained prominence as a new molecular mechanism that regulates many vital functions of the nervous system, including development of synaptic connections and synaptic plasticity. Here, we review the latest findings on the role of proteolysis in sculpting the nervous system through control of axonal growth, axonal and dendritic pruning, and regulation of synaptic size and number. We also discuss how protein degradation functions in synaptic plasticity and the roles of local proteolysis in neuronal compartments. In addition, we describe how proteolysis is associated with Alzheimer's disease and ataxia. Furthermore, we highlight the recent approaches that exploit components of the ubiquitin-proteasome pathway for amelioration of these diseases in animal models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17950927     DOI: 10.1016/j.tins.2007.08.005

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  40 in total

1.  Ubiquitin homeostasis is critical for synaptic development and function.

Authors:  Ping-Chung Chen; Bula J Bhattacharyya; John Hanna; Heather Minkel; Julie A Wilson; Daniel Finley; Richard J Miller; Scott M Wilson
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

2.  Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Authors:  Pradeep Kurup; Yongfang Zhang; Jian Xu; Deepa V Venkitaramani; Vahram Haroutunian; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

3.  Effects of acute dieldrin exposure on neurotransmitters and global gene transcription in largemouth bass (Micropterus salmoides) hypothalamus.

Authors:  Christopher J Martyniuk; April Feswick; Daniel J Spade; Kevin J Kroll; David S Barber; Nancy D Denslow
Journal:  Neurotoxicology       Date:  2010-05-11       Impact factor: 4.294

4.  Amyloid β-induced FOXRED2 mediates neuronal cell death via inhibition of proteasome activity.

Authors:  SangMi Shim; WonJae Lee; HaeWon Chung; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2010-10-23       Impact factor: 9.261

Review 5.  Think locally: control of ubiquitin-dependent protein degradation in neurons.

Authors:  Alexandra Segref; Thorsten Hoppe
Journal:  EMBO Rep       Date:  2008-12-12       Impact factor: 8.807

6.  Ubiquitination acutely regulates presynaptic neurotransmitter release in mammalian neurons.

Authors:  Gina V Rinetti; Felix E Schweizer
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

7.  Ubiquitin C-terminal hydrolase L1 (UCH-L1) loss causes neurodegeneration by altering protein turnover in the first postnatal weeks.

Authors:  Anna T Reinicke; Karoline Laban; Marlies Sachs; Vanessa Kraus; Michael Walden; Markus Damme; Wiebke Sachs; Julia Reichelt; Michaela Schweizer; Philipp Christoph Janiesch; Kent E Duncan; Paul Saftig; Markus M Rinschen; Fabio Morellini; Catherine Meyer-Schwesinger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-28       Impact factor: 11.205

8.  Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356.

Authors:  Philip J Dolan; Youngnam N Jin; Woong Hwang; Gail V W Johnson
Journal:  FEBS Lett       Date:  2011-10-05       Impact factor: 4.124

9.  The Anaphase-Promoting Complex (APC) ubiquitin ligase regulates GABA transmission at the C. elegans neuromuscular junction.

Authors:  Jennifer R Kowalski; Hitesh Dube; Denis Touroutine; Kristen M Rush; Patricia R Goodwin; Marc Carozza; Zachary Didier; Michael M Francis; Peter Juo
Journal:  Mol Cell Neurosci       Date:  2013-12-07       Impact factor: 4.314

10.  HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q.

Authors:  Sarah E Lloyd; Martin Rossor; Nick Fox; Simon Mead; John Collinge
Journal:  BMC Med Genet       Date:  2009-09-15       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.